Use of direct oral anticoagulants and low molecular weight heparin in venous thromboembolism associated with cancer: real-world evidence in Argentina

References

• Kimpton M, Carrier M. What’s new in the prevention and treatment of cancer-associated thrombosis? Hematology Am Soc Hematol Educ Program. 2019;2019(1):158–166. doi: 10.1182/hematology.2019000023
   PubMedGoogle Scholar
• Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–e81. doi: 10.1016/S1470-2045(19)30336-5
   PubMed Web of Science ®Google Scholar
• Kraaijpoel N, van Es N, Bleker SM, et al. Clinical impact and course of anticoagulant-related major bleeding in cancer patients. Thromb Haemost. 2018;118(1):174–181. doi: 10.1160/TH17-04-0274
   PubMed Web of Science ®Google Scholar
• Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891–1894. doi: 10.1111/jth.14219
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. doi: 10.1200/JCO.19.01461
   PubMed Web of Science ®Google Scholar
• Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545–e608. doi: 10.1016/j.chest.2021.07.055
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624. doi: 10.1056/NEJMoa1711948
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. doi: 10.1200/JCO.2018.78.8034
   PubMed Web of Science ®Google Scholar
• McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2019;18(2):411–421. doi: 10.1111/jth.14662
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607. doi: 10.1056/NEJMoa1915103
   PubMed Web of Science ®Google Scholar
• Giustozzi M, Agnelli G, Del Toro-Cervera J, Klok FA, Rosovsky RP, Martin AC, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost. 2020;120(7):1128–1136. doi: 10.1055/s-0040-1712098
   PubMed Web of Science ®Google Scholar
• Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781–790. doi: 10.1016/j.chest.2021.09.037
   PubMed Web of Science ®Google Scholar
• Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, et al. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2018;16(7):1288–1295. doi: 10.1111/jth.14156
   PubMed Web of Science ®Google Scholar
• Larsen TL, Garresori H, Brekke J, et al. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up. J Thromb Haemost. 2022;20(5):1166–1181. doi: 10.1111/jth.15666
   PubMed Web of Science ®Google Scholar
• Chistolini A, Serrao A, Assanto GM, et al. Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients. Ann Hematol. 2023;102(9):2599–2605. doi: 10.1007/s00277-023-05369-1
   PubMed Web of Science ®Google Scholar
• Soff GA, Mones J, Wilkins C, et al. Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Res Pract Thromb Haemost. 2019;3(3):349–356. doi: 10.1002/rth2.12215
   PubMed Web of Science ®Google Scholar
• Mahé I, Agnelli G, Ay C, et al. Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study. Thromb Haemost. 2022;122(4):646–656. doi: 10.1055/a-1647-9896
   PubMed Web of Science ®Google Scholar
• Pignataro BS, Nishinari K, Cavalcante RN, et al. Oral rivaroxaban for the treatment of Symptomatic venous thromboembolism in 400 patients with active cancer: a single-center experience. Clin Appl Thromb Hemost. 2017;23(7):883–887. doi: 10.1177/1076029616677800
   PubMed Web of Science ®Google Scholar
• Xavier FD, Hoff PMG, Braghiroli MI, et al. Rivaroxaban: an affordable and effective alternative in cancer-related thrombosis? J Glob Oncol. 2017;3(1):15–22. doi: 10.1200/JGO.2015.002527
   PubMedGoogle Scholar
• Bergmark BA, Kamphuisen PW, Wiviott SD, et al. Comparison of events across bleeding scales in the ENGAGE AF-TIMI 48 trial. Circulation. 2019;140(22):1792–1801. doi: 10.1161/CIRCULATIONAHA.119.041346
   PubMed Web of Science ®Google Scholar
• van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102(9):1494–1501. doi: 10.3324/haematol.2017.169060
   PubMed Web of Science ®Google Scholar
• Martinez BK, Sheth J, Patel N, et al. Systematic review and meta-analysis of real-world studies evaluating rivaroxaban for cancer-associated venous thrombosis. Pharmacotherapy. 2018;38(6):610–618. doi: 10.1002/phar.2113
   PubMed Web of Science ®Google Scholar